Кардиоонкология: влияние химиотерапевтических препаратов и лучевой терапии на сердечно-сосудистую систему

Автор: Дундуа Давид Петрович, Стаферов Антон Валерьевич, Сорокин Александр Вячеславович, Кедрова Анна Генриховна

Журнал: Клиническая практика @clinpractice

Статья в выпуске: 4 (28), 2016 года.

Бесплатный доступ

Противораковая терапия может стать причиной стенокардии, острого коронарного синдрома, мозгового инсульта, критической ишемии конечностей, аритмий и сердечной недостаточности. Новая специализация в кардиологии, называемая кардиоонкологией, изучает осложнения со стороны сердечно-сосудистой системы, возникающие на фоне лечения онкологического заболевания. Первая часть литературного обзора, основанного на публикациях последних десятилетий, посвящена определению кардионкологии, механизмам развития кардиотоксичности и сосудистой токсичности при применении ряда противоопухолевых препаратов, негативно влияющих на сердечно-сосудистую систему.

Еще

Кардиоонкология, онкокардиология, кардиотоксичность, химиотерапия, радиационное поражение сердца

Короткий адрес: https://sciup.org/143164616

IDR: 143164616

Список литературы Кардиоонкология: влияние химиотерапевтических препаратов и лучевой терапии на сердечно-сосудистую систему

Cancer Data and Statistics. 2011. http://www.cdc. gov/cancer/dcpc/data/. Accessed on 10 June 2015.
Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med 2014;24:285-295.
Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur Heart J. 2016 Sep 21;37(36):2768-2801.
Iliescu C, et al. SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catheterization Laboratory. Catheter Cardiovasc Interv 2016; Apr;87(5):E202-23 DOI: 10.1002/ccd.26379
Plana JC, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911-39.
Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300(6):278-83.
Buzdar AU, Marcus C, Smith TL, et al. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer.1985;55(12):2761-5.
Suter TM, Ewer M S. Cancer drugs and the heart: importance and management. Euro Heart J. 2013; 34:1102-1111.
Perez EA, Romond EH, Suman VJ, Jeong JH, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-3373.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
Kerkela R, Grazette L, Yacobi R, Iliescu C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.
Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-1237.
Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J 1988;9:552-556.
Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987;19:253-256.
Gianni M, Dentali F, Lonn E. 5 flourouracil-induced apical ballooning syndrome: A case report. Blood Coagul Fibrinolysis 2009;20:306-308.
Sudhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004;15:661-664.
Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013 Dec; 39(8):974-84 DOI: 10.1016/j.ctrv.2013.03.005
Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: More than just vasospastic angina. Intern Med J 2010;40:303-307.
Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine induced chest pain relieved by diltiazem. Am J Cardiol 2012; 110:1623-1626.
Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res 2005;10:498-501.
Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990;8:583-586.
Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs 2008;19:927-929.
Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol 2014;26:E18-E20.
Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991;12:748-750.
Chen XL, Lei YH, Liu CF, et al. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: A meta-analysis. PLoS One 2013;8:e66721.
Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239.
Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011;22:1404-1412.
Sen F, Yildiz I, Basaran M, et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J Buon 2013;18:775-781.
Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56:675-681.
Kappers MH, de Beer VJ, Zhou Z, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012;59:151-157.
Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009;54:512-515.
Porto I, Leo A, Miele L, et al. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010;7:476-480.
Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz 2011;36:348-351.
Holm PW, Slart RH, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: A dual role for VEGF. Ann Med 2009;41:257-264.
Duran JM, Makarewich CA, Trappanese D, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res 2014;114:1700-1712.
Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Ann Oncol 2009;20:1535-1542.
Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-539.
Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012;12:337-340.
Arunprasath P, Gobu P, Dubashi B, Satheesh S, Balachander J. Rituximab induced myocardial infarction: A fatal drug reaction. J Cancer Res Ther 2011;7:346-348.
Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503-509.
Dieckmann KP, Gerl A, Witt J, Hartmann JT. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010;21:1607-1611.
Parekh A, Chen MH, Graham P, et al. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer 2015 Feb;13 (1):e1-6.
Ziehr DR, Chen MH, Zhang D, et al. Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 2014;116:358-365.
Carles Galceran J, Bastus Piulats R, Martin-Broto J, et al. A phase II study of vinorelbine and estramustine in patients with hormone resistant prostate cancer. Clin Transl Oncol 2005;7:66-73.
Nakagami Y, Ohori M, Sakamoto N, et al. Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. Int J Urol 2010;17: 629-634.
Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: Results of a meta-analysis. Cancer 2004;101:2755-2759.
Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65:565-573.
van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-1409.
Cahill TJ, Chowdhury O, Myerson SG, et al. Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: Diagnosis and follow-up by cardiac magnetic resonance imaging. Circulation 2011;123:e370-e372.
Sargsyan Z, Higgins C, Alexandrescu S, Ott DA, Jain SK. Acute promyelocytic leukemia as a cause of intracoronary drug-eluting stent thrombosis. Tex Heart Inst J 2012;39:416-419.
Kupeli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol 2010;28:1025-1030.
Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 2007;69:1484-1495.
Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007;25:3031-3037.
Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 2011;378:1707-1716.
Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
Lee CC, Su YC, Ho HC, et al. Increased risk of ischemic stroke in young nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2011;81:e833-e838.
Lam WW, Leung SF, So NM, et al. Incidence of carotid stenosis in nasopharyngeal carcinoma patients after radiotherapy. Cancer 2001;92:2357-2363.
Dorresteijn LD, Kappelle AC, Boogerd W, et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 2002;20:282-288.
Cheng SW, Ting AC, Lam LK, Wei WI. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2000;126:517-521.
Al-Mubarak N, Roubin GS, Iyer SS, et al. Carotid stenting for severe radiation-induced extracranial carotid artery occlusive disease. J Endovasc Ther 2000;7:36-40.
Ting AC, Cheng SW, Yeung KM, et al. Carotid stenting for radiation-induced extracranial carotid artery occlusive disease: Efficacy and midterm outcomes. J Endovasc Ther 2004;11:53-59.
Houdart E, Mounayer C, Chapot R, Saint-Maurice JP, Merland JJ. Carotid stenting for radiation-induced stenoses: A report of 7 cases. Stroke 2001;32:118-121.
Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy.JAMA 2003;290:2831-2837.
De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-937.
Milutinovic J, Darcy M, Thompson KA. Radiation-induced renovascular hypertension successfully treated with transluminal angioplasty: Case report. Cardiovasc Intervent Radiol 1990;13:29-31.
Saka B, Bilge AK, Umman B, et al. Bilateral renal artery stenosis after abdominal radiotherapy for Hodgkin’s disease. Int J Clin Pract 2003;57:247-248.
Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 2008;72:563-568.
Saliou C, Julia P, Feito B, Renaudin JM, Fabiani JN. Radiation-induced arterial disease of the lower limb. Ann Vasc Surg 1997;11:173-177.

Еще

Статья научная